

## Medicare Chronic Condition Counts

**Table B.1.b.** Medicare beneficiary counts\* for other chronic or disabling conditions\*\* using fee-for-service (FFS) claims, 2013–2022

Other chronic or disabling condition**	2013 (n=55,206,238)	2014 (n=56,767,788)	2015 (n=58,294,195)	2016 (n=59,818,481)	2017 (n=61,405,844)
ADHD, conduct disorders, and hyperkinetic syndrome	298,871	326,709	355,902	371,631	370,397
Alcohol use disorders	732,381	764,204	825,964	934,430	883,744
Anxiety disorders	4,534,416	4,917,340	5,363,362	5,943,896	6,369,851
Autism spectrum disorders	52,909	59,547	67,490	77,271	85,195
Bipolar disorder	1,223,628	1,269,527	1,310,389	1,334,303	1,330,154
Cerebral palsy	115,067	117,297	120,033	123,887	126,945
Cystic fibrosis and other metabolic developmental disorders	173,240	187,898	226,451	280,012	305,828
Depressive disorders	5,659,832	5,889,370	6,106,958	6,196,911	6,283,284
Drug use disorders	754,482	820,462	948,290	1,171,071	1,317,103
Epilepsy	910,420	930,318	956,169	1,003,628	1,033,873
Fibromyalgia, chronic pain, and fatigue	4,139,155	4,427,148	5,192,119	6,682,539	7,784,424
Human immunodeficiency virus and/or acquired immunodeficiency syndrome (HIV/AIDS)	147,210	150,459	151,418	151,283	150,711
Intellectual disabilities and related conditions	357,092	359,923	365,945	376,287	380,346
Learning disabilities	28,945	32,639	40,667	64,042	80,073
Leukemias and lymphomas	496,864	514,587	547,290	595,748	622,011
Liver disease, cirrhosis, and other liver conditions, except hepatitis	1,247,404	1,307,315	1,409,495	1,558,420	1,698,276
Migraine and chronic headache	721,164	772,930	864,465	1,030,058	1,148,525
Mobility impairments	963,001	963,750	991,980	1,070,723	1,122,816
Multiple sclerosis and transverse myelitis	205,645	210,567	215,713	222,520	228,047
Muscular dystrophy	20,423	20,262	21,805	24,567	25,531
Obesity	3,538,780	4,024,234	4,631,516	5,591,923	6,602,943
Opioid use disorder	408,664	471,261	581,189	801,745	939,868
Other developmental delays	42,070	44,572	47,619	46,458	43,239
Peripheral vascular disease (PVD)	4,202,839	4,206,560	4,282,247	4,496,886	4,549,198
Personality disorders	213,797	216,322	291,901	490,953	578,653
Post-traumatic stress disorder (PTSD)	306,150	343,484	386,381	431,058	466,322
Pressure and chronic ulcers	1,733,659	1,734,942	1,736,920	1,716,956	1,698,166
Schizophrenia	720,969	724,034	730,960	736,838	734,437
Schizophrenia and other psychotic disorders	1,454,124	1,474,784	1,477,723	1,334,613	1,217,847
Sensory — blindness and visual impairment	326,026	315,649	290,799	258,737	227,725
Sensory — deafness and hearing impairment	1,570,260	1,672,972	1,771,471	1,868,223	1,964,037
Sickle cell disease†	18,433	18,602	18,766	18,901	18,891
Spina bifida and other congenital anomalies of the nervous system	54,471	54,973	55,595	55,439	53,878
Spinal cord injury	99,512	98,612	129,110	221,947	268,670
Tobacco use	2,953,690	3,075,416	3,174,722	3,187,591	3,514,889

Other chronic or disabling condition**	2013 (n=55,206,238)	2014 (n=56,767,788)	2015 (n=58,294,195)	2016 (n=59,818,481)	2017 (n=61,405,844)
Traumatic brain injury and nonpsychotic mental disorders due to brain damage	142,160	145,593	155,787	163,243	165,904
Viral hepatitis (general)	446,128	460,361	483,194	504,087	506,919

\* Includes all Medicare beneficiaries who were eligible for or enrolled in Medicare on or after January 1, YYYY.

\*\* The Chronic Conditions Warehouse (CCW) team may have counted beneficiaries in more than one condition category. All conditions except for sickle cell disease have a two-year look-back time period (reference period). Refer to the CCW website for more information, including the algorithms, for these other chronic or disabling conditions.

† This condition has a five-year look-back period. Refer to the CCW website for more information, including the algorithms, for these other chronic or disabling conditions.

**NOTE:** These counts consider FFS administrative claims only. The beneficiaries included in these counts may have any combination of Medicare coverage, including full or partial FFS and/or health maintenance organization (HMO) coverage. The application of coverage restrictions/criteria will impact the size of these samples.

**Table B.1b.** Medicare beneficiary counts\* for other chronic or disabling conditions\*\* using fee-for-service (FFS) claims, 2013–2022

Other chronic or disabling condition**	2018 (n=62,930,784)	2019 (n=64,430,729)	2020 (n=65,901,907)	2021 (n=67,041,110)	2022 (n=68,266,781)
ADHD, conduct disorders, and hyperkinetic syndrome	388,741	401,915	391,514	373,849	372,044
Alcohol use disorders	837,377	840,249	803,023	758,704	733,112
Anxiety disorders	6,651,163	6,842,100	6,763,051	6,583,920	6,516,497
Autism spectrum disorders	94,266	103,441	107,233	110,773	116,969
Bipolar disorder	1,351,651	1,360,185	1,311,079	1,226,986	1,188,768
Cerebral palsy	129,278	130,259	125,616	119,766	117,619
Cystic fibrosis and other metabolic developmental disorders	322,341	333,955	323,927	313,672	317,224
Depressive disorders	6,482,503	6,592,989	6,406,612	6,086,055	5,965,824
Drug use disorders	1,380,369	1,418,935	1,358,143	1,259,394	1,206,584
Epilepsy	1,046,112	1,043,124	1,002,344	936,355	902,219
Fibromyalgia, chronic pain, and fatigue	8,177,457	8,323,538	7,927,155	7,654,172	7,777,382
Human immunodeficiency virus and/or acquired immunodeficiency syndrome (HIV/AIDS)	149,834	147,952	141,065	132,836	125,555
Intellectual disabilities and related conditions	385,066	383,333	364,965	344,803	334,787
Learning disabilities	85,337	89,167	89,262	87,057	87,086
Leukemias and lymphomas	635,254	645,325	638,297	635,899	636,267
Liver disease, cirrhosis, and other liver conditions, except hepatitis	1,795,473	1,876,092	1,861,321	1,878,740	1,941,035
Migraine and chronic headache	1,205,402	1,252,050	1,214,613	1,191,875	1,223,662
Mobility impairments	1,130,833	1,126,428	1,084,163	1,013,692	987,636
Multiple sclerosis and transverse myelitis	229,689	229,509	221,791	212,609	206,846
Muscular dystrophy	25,182	24,655	23,217	21,811	21,970
Obesity	7,437,524	7,635,182	7,101,388	6,843,020	6,837,891
Opioid use disorder	966,013	982,805	951,871	907,711	902,758
Other developmental delays	45,646	48,110	48,170	47,166	47,457
Peripheral vascular disease (PVD)	4,588,837	4,655,001	4,490,654	4,276,372	4,324,302
Personality disorders	569,379	556,256	508,076	452,157	413,466
Post-traumatic stress disorder (PTSD)	504,627	536,651	531,812	508,891	497,487
Pressure and chronic ulcers	1,713,961	1,720,548	1,693,353	1,641,542	1,631,314
Schizophrenia	733,367	723,904	692,052	639,269	605,622
Schizophrenia and other psychotic disorders	1,191,409	1,158,497	1,096,487	1,001,670	950,124
Sensory — blindness and visual impairment	191,017	164,280	162,722	151,980	146,885
Sensory — deafness and hearing impairment	2,063,625	2,148,532	2,053,192	2,049,189	2,209,458
Sickle cell disease†	18,761	18,586	18,228	17,607	16,933
Spina bifida and other congenital anomalies of the nervous system	55,026	59,103	59,085	58,558	60,755
Spinal cord injury	264,767	267,094	251,027	237,405	244,961
Tobacco use	3,809,329	3,777,895	3,475,311	3,129,788	2,944,499
Traumatic brain injury and nonpsychotic mental disorders due to brain damage	167,735	166,139	153,158	137,523	133,691
Viral hepatitis (general)	492,043	465,572	416,988	363,361	325,038

\* Includes all Medicare beneficiaries who were eligible for or enrolled in Medicare on or after January 1, YYYY.

\*\* The Chronic Conditions Warehouse (CCW) team may have counted beneficiaries in more than one condition category. All conditions except for sickle cell disease have a two-year look-back time period (reference period). Refer to the CCW website for more information, including the algorithms, for these other chronic or disabling conditions.

† This condition has a five-year look-back period. Refer to the CCW website for more information, including the algorithms, for these other chronic or disabling conditions.

**NOTE:** These counts consider FFS administrative claims only. The beneficiaries included in these counts may have any combination of Medicare coverage, including full or partial FFS and/or health maintenance organization (HMO) coverage. The application of coverage restrictions/criteria will impact the size of these samples.